ENDPOINTS

Biotech’s survival guide; What tariffs could mean for p...

Welcome back to Endpoints Weekly! This week's recap kicks off with Andrew Dunn's...

FDA unveils plan to replace animal testing with organoids

Newly-installed FDA Commissioner Marty Makary announced a plan to begin phasing ...

Bristol Myers' immunotherapy combo nets two new approvals

Bristol Myers Squibb’s combined immunotherapies Opdivo and Yervoy won approval t...

Recruiters say some biopharmas pause hiring as they str...

An already bleak biotech market has become more daunting for job seekers, partic...

Argenx’s Vyvgart Hytrulo syringe is approved in the US;...

Plus, news about Protagonist Therapeutics, Pfizer and Keros Therapeutics: Ar...

CDMOs anticipate inspection bottlenecks after FDA firings

CDMOs fear that FDA site inspections might slow down due to the mass staffing cu...

Ira Mellman joins PICI; ViiV Healthcare CMO replaces Ch...

After 17 years at Genentech, Ira Mellman is joining the Parker Institute for Can...

Tome Bio founders wrangle ‘jumping genes’ for new gene ...

Two Boston scientists say they have developed a new gene editing tool based on m...

FDA is reversing return-to-office mandate for some workers

Less than a month after the Trump administration ordered all FDA employees to co...

Novartis follows Lilly and J&J in announcing multibilli...

With US tariffs on pharmaceuticals likely to come "very soon," another of the wo...

RFK Jr. talks vaccines, job cuts in his first network i...

In the roughly two months since Robert F. Kennedy Jr. took over as head of HHS, ...

Insight Partners' Scott Barclay on mental health investing

For years, investors have poured billions into mental health startups, making it...

DHL pours €2B into healthcare logistics; OXB revenues o...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential ne...

#AAN25: J&J, argenx keep rolling out myasthenia gravis ...

Last weekend, researchers gathered in San Diego for the American Academy of Neur...

Alzheon’s amyloid-targeting pill fails another Alzheime...

Alzheon’s controversial, decade-long bet that a failed Alzheimer’s drug could of...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.